# Invivyd

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/invivyd

- Industry: Biotechnology
- Headquarters: Waltham, US
- Website: www.invivy.com
- Total disclosed funding: $466M
- Latest round: Series C (Apr 16, 2021)
- Investors on record: 15

## About

Based in Massachusetts, US, and founded in 2020, Invivyd, Inc. (NASDAQ:IVVD), formerly known as Adagio Therapeutics, Inc. is a biotech that develops antibodies to treat or prevent Covid-19. The company was co-founded by Laura Walker and Tillman Gerngross (CEO). In April 2021, the company received USD 336 million in Series C funding from RA Capital Management, including Redmile Group, Federated Hermes, Foresite Capital, ArrowMark Partners, PremjiInvest, Fidelity Management & Research Company, LLC, OrbiMed, Polaris Partners, Mithril, GV, Population Health Partners, Adimab, and Omega Funds. The company is listed on the Nasdaq under the symbol ADGI. As of 2021, the company employs 68 people. 
 
Adagio Therapeutics, Inc. offers antibodies intended to neutralize and provide treatment for emergent coronaviruses, including SARS-CoV-2, SARS-CoV-1, and other related coronaviruses. The company also focuses on phase 1 study of ADG20 (a highly potent and broad mAb therapeutic candidate for both the treatment and prevention of COVID-19), a pivotal phase 1/2/3 clinical trial in high-risk individuals with mild or moderate COVID-19.
 
Adagio Therapeutics, Inc. plans to use its Series C funding to support the rapid advancement of novel ADG20 antibodies for the treatment and prevention of COVID-19.

## Funding rounds

- Series C, Apr 16, 2021, $336M — OrbiMed Advisors, Polaris Partners, Fidelity Investments, GV, ArrowMark Partners, Omega Funds, MDT Advisers, Foresite Capital, Redmile Group, PremjiInvest, Adimab, LLC, Mithril, RA Capital Management, Population Health Partners
- Series B, Oct 30, 2020, $80M — OrbiMed Advisors, Polaris Partners, Fidelity Investments, GV, Omega Funds, Mithril, Population Health Partners
- Series A, Jul 16, 2020, $50M — OrbiMed Advisors, Polaris Partners, Fidelity Investments, GV, Mithril, M28 Capital

## Investors

- OrbiMed Advisors (https://capitalatlas.ai/funds/orbimed-advisors) — Series A, Series B, Series C
- Polaris Partners (https://capitalatlas.ai/funds/polaris-partners) — Series A, Series B, Series C
- Fidelity Investments (https://capitalatlas.ai/funds/fidelity-investments) — Series A, Series B, Series C
- GV (https://capitalatlas.ai/funds/gv) — Series A, Series B, Series C
- Mithril (https://capitalatlas.ai/funds/mithril) — Series A, Series B, Series C
- M28 Capital — Series A
- Omega Funds (https://capitalatlas.ai/funds/omega-funds) — Series B, Series C
- Population Health Partners (https://capitalatlas.ai/funds/population-health-partners) — Series B, Series C
- ArrowMark Partners — Series C
- MDT Advisers — Series C
- Foresite Capital (https://capitalatlas.ai/funds/foresite-capital) — Series C
- Redmile Group (https://capitalatlas.ai/funds/redmile-group) — Series C
- PremjiInvest (https://capitalatlas.ai/funds/premjiinvest) — Series C
- Adimab, LLC — Series C
- RA Capital Management (https://capitalatlas.ai/funds/ra-capital-management) — Series C